top of page
Search

Systemic Sclerosis Limited vs Diffuse

TL;DR

Rheum: Systemic Sclerosis (Limited vs. Diffuse) is a high-yield MRCP Part 1 topic focused on differentiating disease subsets by skin involvement, antibodies, and complications. Limited disease (CREST) progresses slowly and is linked to pulmonary hypertension, whereas diffuse disease is aggressive with early organ fibrosis, especially lungs and kidneys. Recognising subtype patterns and antibody associations is essential for scoring marks in exam questions.


Why this matters

Systemic sclerosis is a classic integrative topic in MRCP Part 1, bridging immunology, rheumatology, nephrology, and cardiology. Exam questions rarely ask for definitions—they test pattern recognition: subtype, antibody, and complication.

If you can quickly identify whether the patient has limited or diffuse systemic sclerosis, you can predict complications and choose the correct answer.

For broader preparation, review the MRCP Part 1 overview to align your revision strategy.


Core sections

1. Definition and Pathophysiology

Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterised by:

  • Endothelial dysfunction and microvascular injury

  • Autoantibody production

  • Progressive fibrosis of skin and internal organs

The underlying mechanism is excess collagen deposition, leading to:

  • Skin thickening

  • Organ dysfunction

  • Vascular complications

2. Limited vs Diffuse Systemic Sclerosis (High-Yield Table)

Feature

Limited SSc (CREST)

Diffuse SSc

Skin involvement

Distal (hands, face)

Proximal + trunk

Onset

Gradual

Rapid

Raynaud’s

Early and prominent

Early

Antibody

Anti-centromere

Anti-Scl-70, anti-RNA polymerase III

Pulmonary HTN

Common (late)

Less common

Interstitial lung disease

Less common

Common (early)

Renal crisis

Rare

Common

Prognosis

Better

Worse

Exam mnemonic:

  • Limited = “Late lung problem (PAH)”

  • Diffuse = “Diffuse early damage”

3. CREST Syndrome (Limited Disease)

CREST is frequently tested:

  • Calcinosis

  • Raynaud’s phenomenon

  • Esophageal dysmotility

  • Sclerodactyly

  • Telangiectasia

Key exam links:

  • Anti-centromere antibodies

  • Digital ulcers

  • Pulmonary arterial hypertension (PAH)

4. Diffuse Systemic Sclerosis

Diffuse disease has rapid progression and early organ involvement.

Clinical features:

  • Widespread skin thickening (including trunk)

  • Early lung fibrosis

  • Cardiac involvement

Key complications:

  • Interstitial lung disease (leading cause of mortality)

  • Scleroderma renal crisis

  • Myocardial fibrosis

5. Most Tested Subtopics (Top 5)

  1. Autoantibodies

    • Anti-centromere → limited

    • Anti-Scl-70 → diffuse

    • Anti-RNA polymerase III → renal crisis

  2. Renal Crisis

    • Acute hypertension + AKI

    • Treat with ACE inhibitors (do not stop if creatinine rises)

  3. Pulmonary Disease

    • Limited → pulmonary hypertension

    • Diffuse → interstitial lung disease

  4. Raynaud’s Phenomenon

    • Often first manifestation

    • Triphasic colour change

  5. Gastrointestinal Involvement

    • Oesophageal dysmotility → reflux

    • Malabsorption from bacterial overgrowth

6. High-Yield Exam Points

  1. Limited disease affects distal skin only

  2. Diffuse disease involves trunk and proximal limbs

  3. Anti-centromere = limited

  4. Anti-Scl-70 = diffuse with lung fibrosis

  5. Anti-RNA polymerase III = renal crisis

  6. ACE inhibitors are first-line in renal crisis

  7. Pulmonary HTN occurs late in limited disease

  8. ILD occurs early in diffuse disease

  9. Raynaud’s is often the first symptom

  10. Prognosis is worse in diffuse disease


Practical examples / mini-cases

Case

A 50-year-old woman presents with long-standing Raynaud’s, tight skin over fingers, and telangiectasia. She reports worsening breathlessness. Antibody testing reveals anti-centromere positivity.

Question: What is the most likely diagnosis and complication?

Answer: Limited systemic sclerosis with pulmonary hypertension

Explanation: Distal skin involvement + CREST features + anti-centromere antibody strongly indicate limited disease. The most important complication is pulmonary arterial hypertension, not renal crisis.

👉 Reinforce your learning with Free MRCP MCQs.


Medical student revising systemic sclerosis notes for MRCP Part 1 exam preparation

Common pitfalls (5 bullets)

  • Mixing up anti-centromere and anti-Scl-70 antibodies

  • Forgetting renal crisis is mainly seen in diffuse disease

  • Assuming pulmonary hypertension occurs early (it is late in limited disease)

  • Missing ACE inhibitor use despite rising creatinine

  • Overlooking GI involvement as a key feature


Practical study-tip checklist

  • Memorise the limited vs diffuse table

  • Learn antibody–disease associations thoroughly

  • Use mnemonics (CREST) for recall

  • Practise scenario-based MCQs

  • Revise complications by subtype

  • Test yourself regularly using Start a mock test


FAQs

1. How can I quickly differentiate limited vs diffuse systemic sclerosis?

Focus on skin distribution and progression: distal and slow suggests limited; proximal and rapid suggests diffuse. Antibodies confirm your suspicion.

2. Which antibody is associated with limited systemic sclerosis?

Anti-centromere antibody is strongly linked to limited disease and CREST syndrome.

3. What is the most dangerous complication of diffuse systemic sclerosis?

Scleroderma renal crisis and interstitial lung disease are the most life-threatening complications.

4. Why are ACE inhibitors used in scleroderma renal crisis?

They reduce glomerular pressure and control hypertension, improving survival—even if creatinine initially rises.

5. Which subtype is associated with pulmonary hypertension?

Pulmonary hypertension is classically seen in limited systemic sclerosis, especially in late disease.


Ready to start?

Systemic sclerosis is a scoring topic if you master pattern recognition. Strengthen your preparation:

For deeper rheumatology revision, explore related topics in our blog section.


Sources

 
 
 

Comments

bottom of page